On Wednesday 9 March, the Minister for Industry, Innovation and Science, the Hon. Christopher Pyne MP, visited the Australian Synchrotron, touring the facility floor before announcing the Australian Government's agreement to the facility’s transfer to the Australian Nuclear Science and Technology Organisation (ANSTO).
While visiting the Micro Crystallography (MX2) beamline Mr Pyne was updated on a new anti-leukaemia drug developed in Australia thanks to the combination of a world-class medical research institute, the best and brightest researchers and access to the Australian Synchrotron’s landmark infrastructure, and partnership with industry, ensuring Australian public hospital patients were the first in the world to access this novel therapy.